Linzess is approved for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults and pediatric patients aged seven years and above. The drug is also approved for treating ...

Shares of Ironwood Pharmaceuticals IRWD were up 26.7% on Jan. 2 after the company announced upbeat revenue guidance for 2026. The company maintained its revenue guidance for full-year 2025, which it ...

On Nov. 10, Ironwood reported solid third-quarter results, beating estimates for both earnings and sales, backed by the high demand for its sole marketed product, Linzess (linaclotide). Concurrently, ...

We recently published a list of 10 Stocks Fall Behind Amid Market Optimism. In this article, we are going to take a look at where Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) stands against other ...

Ironwood Pharmaceuticals IRWD has been witnessing improved demand for its sole marketed product, Linzess (linaclotide), in recent quarters. The company markets Linzess in the United States in ...

Non-GAAP EPS reached $0.14, dramatically ahead of the non-GAAP analyst estimate of $0.02. GAAP revenue of $85.2 million beat expectations by 40.3% Revenue of $85.2 million declined 9.7% compared to ...

Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) is one of the 7 best small-cap drug manufacturing stocks to buy according to hedge funds. On February 26, Citizens analyst Jason Butler maintained an ...

Ironwood Pharmaceuticals, Inc. IRWD has a lot cooking and its spread appeals to the Street's appetite. The pharma firm caught a Buy rating Monday to compound three existing Buys and two Holds — each ...

Shares of Ironwood Pharmaceuticals (IRWD) added ~31% on Friday to hit a new 52-week high after the company set its 2026 revenue outlook ahead of Street forecasts, citing higher net sales from Linzess, ...